Clearside Biomedical

Clearside Biomedical ROE

Delisted

The Return on Equity (ROE) of Clearside Biomedical (CLSD) as of Nov 20, 2026 is 88.41 %. In the previous year, Return on Equity (ROE) was 204.15 % — a change of -56.69% (lower).

ROE

88.41 %

YoY

-56.69%

Last updated:

In 2024, Clearside Biomedical's return on equity (ROE) was 88.41 %, a -56.69% increase from the 204.15 % ROE in the previous year.

The Clearside Biomedical ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2017
-275.35 USD
Jan 1, 2018
-350.64 USD
Jan 1, 2019
-275.72 USD
Jan 1, 2020
-207.88 USD
Jan 1, 2021
1.00 USD
Jan 1, 2022
-310.56 USD
Jan 1, 2023
204.15 USD
Jan 1, 2024
88.41 USD
The Clearside Biomedical ROE history
YEARROEYoY
88.41 %-56.69%
204.15 %-165.74%
-310.56 %-31,139.26%
1.00 %-100.48%
-207.88 %-24.61%
-275.72 %-21.37%
-350.64 %+27.34%
-275.35 %+662.43%
-36.11 %-78.18%
-165.48 %+23.74%
-133.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

ROE Details

Decoding Clearside Biomedical's Return on Equity (ROE)

Clearside Biomedical's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Clearside Biomedical's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Clearside Biomedical's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Clearside Biomedical’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Clearside Biomedical stock

Return on Equity (ROE) of Clearside Biomedical is 88.41 % in 2024.

Return on Equity (ROE) of Clearside Biomedical changed from 204.15 % to 88.41 %, representing a -56.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Clearside Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Clearside Biomedical

All Key Metrics — Clearside Biomedical